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Objectives: To evaluate short-term outcomes of Macroplastique (MPQ) in women with stress urinary
incontinence (SUI) using patient reported outcome and three-dimensional vaginal ultrasound (3DUS).
Materials and methods: After obtaining institutional review board approval, a chart review of non-
neurogenic women that received MPQ for intrinsic sphincter deﬁciency (ISD) was extracted from a
prospective database. Patients were divided into three groups: naïve (Group I), prior incontinence sur-
gery (Group II), and both prior incontinence surgery and bulking agent (Group III). Women with urethral
hypermobility were excluded. Baseline evaluation included a history, physical examination to conﬁrm
SUI, and questionnaires [Urinary Distress Inventory-6 (UDI-6), 1 quality of life (QOL) global score based
on visual analog scale], and in select patients urodynamic studies and/or standing voiding cystogram.
Patient follow up included repeat questionnaires scores and 3DUS to objectively assess MPQ volume.
Success was deﬁned as sufﬁcient improvement after one injection so that a subsequent reinjection/
different SUI operation was not requested at the last follow-up visit. It was hypothesized that Group I
would fare best.
Results: Fifty-nine women met the inclusion criteria. Success rate was 83% for Group I, 70% for Group II,
and 69% for Group III (p ¼ 0.54) at 9 months mean follow up. Fifteen patients underwent a second 3DUS
during follow up with a stable volume, compared to the ﬁrst study (4.5 ± 1.5 vs. 4.4 ± 1.5, p ¼ 0.70),
which conﬁrmed stable volumes over time. Among the failures (N ¼ 15), nine patients proceeded with
reinjection; four patients had fascial slings, and two patients had artiﬁcial sphincters.
Conclusion: As conﬁrmed by 3DUS, Macroplastique appears efﬁcacious as a primary treatment and as a
salvage treatment for SUI due to ISD in the short-term.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Urethral bulking agents (UBA) are an attractive option for
treating stress urinary incontinence (SUI) due to intrinsic sphincter
deﬁciency (ISD), especially for patients desiring a less invasive
treatment. Macroplastique (polydimethylsiloxane) has been used
for the treatment of SUI with demonstrable efﬁcacy as early as 1991
in Europe.1 In Macroplastique, silicone-based particles are incor-
porated within a polyvinylpyrrolidone (PVP) suspension and
are > 100 mM in diameter, which effectively limits migration.Southwestern Medical Cen-
10, USA.
n.edu (P.E. Zimmern).
ciation. Published by Elsevier Taiw
C, et al., Macroplastique outco
015), http://dx.doi.org/10.101Similar to our experience using collagen as a urethral bulking
agent, we have incorporated three-dimensional transvaginal ul-
trasound (3DUS) imaging and patient self-report questionnaires
into our follow-up management algorithm2,3 for Macroplastique
injections. Three-dimensional vaginal ultrasound provides objec-
tive information about the volume of the bulking agent obtained
and its conﬁguration around the urethra. The use of 3DUS is not
widespread or part of standard guidelines; however, it is a tool with
low cost and no morbidity or invasiveness, which helps in deciding
whether patients are suitable for observation, reinjection, or
another modality of treatment for SUI. Three-dimensional vaginal
ultrasound has been integral in our assessment of women receiving
UBA such as Collagen since 3DUS became available at our center in
1999. Among the early studies reporting on Macroplastique, one
series of 60 women included transurethral ultrasound ﬁndings in
nine patients.4 The ultrasound hyperechoic nature ofan LLC. All rights reserved.
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good outcome for at least 1 year after the procedure when it
completely encircled the urethra.5
In line with these early reports, the aim of our study was to
study the short-term outcomes of Macroplastique (MPQ) inwomen
with SUI secondary to ISD by using validated questionnaires (i.e.,
patient reported outcome) and 3DUS imaging (i.e., objective
outcome). Furthermore, the outcomes of three subgroups were
analyzed to broaden the relevance of this new study. Group I
comprised naïve patients. The remaining two groups were more
complicated: Group II, comprised patients with a history of previ-
ous anti-incontinence surgery and Group III comprised patients
with previous anti-incontinence surgery and failed prior collagen
injection. We hypothesized that Group I would fare best.
2. Materials and methods
After receiving approval from the UT Southwestern Institutional
Review Board (IRB), we performed a review of prospectively
collected data on women with SUI who received MPQ. Inclusion
criteria were women with SUI secondary to ISD, a well-supported
urethra, and at least one postoperative follow-up visit with ques-
tionnaires and 3DUS imaging. Exclusion criteria included neuro-
genic bladder, prior pelvic radiation therapy, and women with
urethral hypermobility.
Success was deﬁned as sufﬁcient improvement after one injec-
tion so that a subsequent reinjection/different SUI operation was
not requested by the patient at their last follow-up visit. “Cur-
e”dthe ability to remain dry and not wear any padsdwas deﬁned
as a score of 0 on Question 3 of the Urinary Distress Inventory-6
(UDI-6) in relation to SUI.6 Patients were divided into three sub-
groups: naïve (Group I), prior anti-incontinence surgery (Group II),
and prior anti-incontinence surgery þ collagen injection (Group
III).Fig. 1. Macroplastique on 3DUS has a very hyperechogenic appearance along the urethra (U)
injection. 3DUS ¼ three-dimensional vaginal ultrasound.
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nation, UDI-6, and one global quality of life visual analog scale
(VAS) that asked “If youwere to spend the rest of your lifewith your
urinary condition just the way it is now, how would you feel about
that?” (with a “0” answer being “pleased” and “10” being
“terrible.”)7 In addition, some patients received further workup
such as ofﬁce cystoscopy, voiding cystourethrogram and/or multi-
channel urodynamic studies if the patients were considered for
MPQ reinjection or surgical sling placement. Women with SUI
secondary to ISD and a well-supported urethra were identiﬁed
primarily by examination ﬁndings (Aa point at 3) with demon-
strable SUI during stress maneuvers. Other tools used to conﬁrm a
well-supported urethra in our practice included an angle of  30
on a true lateral voiding cystourethrogram during straining views.
A urodynamic study, when obtained, provided a Valsalva leak point
pressure. The value of the Valsalva leak point pressure to conﬁrm
ISD is typically < 60 cmH2O; but higher values can occur, which
indicates a lesser degree of ISD severity. Baseline urodynamics with
a noninvasive ﬂow test and a postvoid residual by bladder scanwas
obtained at baseline and in follow up. Of note, patients who had
received previous collagen injections had a 3DUS prior to receiving
MPQ, which provided collagen volume and conﬁguration at
baseline.
The MPQ injections were performed in an outpatient basis by
the same urologist (PZ) with the patient under light anesthesia (i.e.,
intravenous sedation or laryngeal mask airway intubation). In
general, in accordance with our prior protocol on Collagen injec-
tion, two injections (2.5 cc  2 or approximately 5 mL) were
delivered at the 3 o'clock and 9 o'clock positions to obtain luminal
coaptation.
The ﬁrst follow-up visit was 6e8 weeks after the MPQ injection
procedure and included questionnaires and 3DUS imaging.2 Sub-
sequent follow up continued on an annual basis and included
questionnaires with or without 3DUS.on (A) longitudinal and (B) transversal images in a naïve patient who was dry after one
ome inwomenwith stress urinary incontinence secondary to intrinsic
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sisting of a senior ultrasound technician and a radiologist with
longstanding experience with collagen measurements by
ultrasound.7
A small ﬁnger-size vaginal probe was introduced in the patient
in supine position. The probe was positioned underneath the ure-
thral meatus and moved alongside the vaginal wall in longitudinal
and transversal directions. The MPQ is very echogenic and easy to
identify (Fig. 1) on each side of the urethral lumen using the Philips
iU22 ultrasound system (Philips, Andover, MA, USA) and a broad
band 3D volume probe (V9-3) with frequency range of 9
mHze3 mHz. This mechanical 3D probe performs automatic
acquisition of volume data sets. Measurements are performed
transversally and axially to provide a volume calculation. The data
collected from the 3DUS included the total UBA volume (including
MPQ and Collagen, if previously injected) and the conﬁguration
(i.e., circumferential versus asymmetric).
Descriptive statistics were provided using the mean and stan-
dard deviation for continuous variables and frequencies and per-
centages for categorical variables. Fisher's exact test (for categorical
variables), the Student t test (for continuous variables, 2 sub-
groups), and analysis of variance (ANOVA; for continuous variables,
3 subgroups) were used to determine differences between sub-
groups. Post hoc t tests were completed for any signiﬁcant ANOVA
comparisons. The paired t test was used to ﬁnd if there were any
differences between the pre- and postoperative VAS-QOL scores
and the 3DUS volume changes between the ﬁrst and second visit
after injection. A mixed model was used to ascertain whether the
3DUS volume after ﬁnal injection decreased signiﬁcantly over time
after being controlled for by the subgroups and number of in-
jections. All statistics were completed using SAS 9.3 (SAS Institute
Inc., Cary, NC, USA).
3. Results
From a prospective database of 72 patients from July 2011 to
December 2013 who received MPQ, 59 women met inclusionTable 1
Baseline group comparison, based on prior stress urinary incontinence surgical history.
Naïve
(n ¼ 23)
Prior
(n ¼
Age (y) 64.1 ± 8.1 65.0
Parity 1.9 ± 1.0 2.8 ±
BMI 26.0 ± 5.3 28.6
Duration of follow up (mo) 7.2 ± 5.9 8.7 ±
Preoperative VLPP
Mean ± SD 53.6 ± 17.2 75.1
<60 4/13 (31) 8/13
60 9/13 (69) 5/13
(n ¼ 19) (n ¼
Qmax 15.5 ± 7.7 13.8
Postvoid residual
No residual 16/19 (84) 15/1
Residual 3/19 (16) 3/18
UDI6 Total score 11.4 ± 3.6 10.4
UDI6 Q2 e Urge Incontinence
0 or 1 2/10 (20) 5/18
2 or 3 8/10 (80) 13/1
UDI6 Q3 e Stress incontinence
0 or 1 0/10 (0) 1/19
2 or 3 10/10 (100) 18/1
UDI6 Q5 e Emptying
0 or 1 5/10 (50) 15/1
2 or 3 5/10 (50) 4/19
Data are presented as n/N (%) or mean ± SD.
UDI6 score of 0, 1 ¼ none or rare; Score of 2, 3 ¼ moderate or severe.
BMI ¼ body mass index; Q2 ¼ Question 2; Q5 ¼ Question 5; Qmax ¼ XX; UDI6 ¼ Urina
Please cite this article in press as: Rosenfeld EC, et al., Macroplastique outco
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urinary retention lasting < 48 hours occurred in ﬁve women. At a
mean follow up of 8.5 ± 7.2 months, the success rate was 83% for
Group I, 70% for Group II, and 69% for Group III. The cure rate was
17% for Group I, 9% for Group II, and 38% for Group III. The mean age
(p ¼ 0.21) and BMI (p ¼ 0.28) were comparable across the three
groups, as was the mean duration of follow up (p ¼ 0.46; Table 1).
Group II had a signiﬁcantly higher parity than Group I (p ¼ 0.046).
For naïve patients, the mean volume of MPQ injected was 4.43 mL
(range, 2.5e5 mL) with the mean volume measured on ﬁrst 3DUS
after MPQ at 3.85 (range, 1.77e5.91). This gave a volume retention
rate of 87%. At this ﬁrst 3DUS study, 72% of studies indicated a
circumferential conﬁguration for MPQ.
Among the 15 failures, there was no signiﬁcant difference be-
tween the groupsdfour failures were from Group I; seven failures
from Group II, and four failures from Group III (p ¼ 0.59) (Table 2).
The pretreatment UDI-6 scores for Question 3 in the success group
were generally more favorable than those of the failure group.
Among the failures, nine patients proceeded with reinjection; four
patients with slings; and two patients with artiﬁcial urinary
sphincters. Themean timebetween theﬁrst and the repeat injection
was 10 months (range, 3e19), whereas the mean time between the
ﬁrst injection and a secondary sling was 8.5 months (range, 2e16).
Fifteen patients underwent a second 3DUS during the follow up
(mean interval of 9 months after the ﬁrst 3DUS) with a stable
volume, compared to ﬁrst study (4.5 ± 1.5 vs. 4.4 ± 1.5, respectively;
p ¼ 0.70). Four patients with a prior collagen injection also un-
derwent a second 3DUSwith similar ﬁndings (5.3 ± 1.3 vs. 4.9 ± 1.4;
p ¼ 0.35). In a mixed model that controlled for the number of in-
jections and prior urological history, time since the last injection
was not a signiﬁcant factor in ultrasound volume after the last in-
jection (mean follow up, 6.5 months; p ¼ 0.46).
Parameters related to voiding such as Question 5 of the UDI-6,
maximum ﬂow, or postvoid residuals were not affected by MPQ
injection across the three groups.
Of patients that had VAS-QOL recorded during their pre- and
postoperative visits, there was signiﬁcant improvement whethersurgery
23)
Prior surgery þ collagen
(n ¼ 13)
p
± 11.3 70.1 ± 10.2 0.21
1.3 1.9 ± 1.3 0.046
± 6.3 27.2 ± 3.9 0.28
7.4 10.3 ± 8.8 0.46
± 40.4 65.4 ± 28.5 0.22
(62) 4/7 (57) 0.29
(38) 3/7 (43)
18) (n ¼ 9)
± 8.5 20.1 ± 15.8 0.30
8 (83) 6/9 (67) 0.56
(17) 3/9 (33)
± 3.9 9.5 ± 4.2 0.59
(28) 3/8 (38) 0.79
8 (72) 5/8 (63)
(5) 2/8 (25) 0.17
9 (95) 6/8 (75)
9 (79) 6/8 (75) 0.29
(21) 2/8 (25)
ry Distress Inventory-6; VLPP ¼ Valsalva leak point pressure.
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Table 2
Differences between the patients that only received one injection and had no other
surgery versus patients that had a repeat injection or reoperation.
Success group
(n ¼ 44)
Failure group
(n ¼ 15)
p
Prior History
Naïve 19/23 (83) 4/23 (17) 0.59
Prior surgery 16/23 (70) 7/23 (30)
Prior surgery þ prior collagen 9/13 (69) 4/13 (31)
Preoperative VLPP (cm H2O)
Mean ± SD 62.6 ± 31.4 71.9 ± 31.3 0.49
<60 11/16 (69) 5/16 (31) 0.22
60 15/17 (88) 2/17 (12)
(n ¼ 36) (n ¼ 10)
Qmax (mL/s) 15.8 ± 10.5 15.5 ± 8.8 0.94
Postvoid residual (mL)
No residual 29/37 (78) 8/37 (22) 1.00
Residual 7/9 (78) 2/9 (22)
UDI6 Total 10.2 ± 4.0 11.2 ± 3.4 0.44
UDI6 Q2 e Urge Incontinence
0 or 1 8/10 (80) 2/10 (20) 0.69
2 or 3 18/26 (69) 8/26 (31)
UDI6 Q3 e Stress Incontinence
0 or 1 3/3 (100) 0/3 (0) 0.54
2 or 3 23/34 (68) 11/34 (32)
UDI6 Q5 e Emptying
0 or 1 19/26 (73) 7/26 (27) 0.70
2 or 3 7/11 (64) 4/11 (36)
Data are presented as n/N (%) or mean ± SD.
UDI6 score of 0 or 1 ¼ ”none“ or “rare”; UDI6 score of 2 or 3 ¼ “moderate” or
“severe.”
Q2 ¼ Question 2; Q5 ¼ Question 5; Qmax ¼ XX; UDI6 ¼ Urinary Distress Inventory-
6; VLPP ¼ Valsalva leak point pressure.
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group reported a 3.3 ± 3.7 (p ¼ 0.0003) improvement in the ab-
solute value score. The failure group reported a 2.7 ± 3.4 (p ¼ .03)
improvement. The difference between the VAS-QOL scores for the
success and failure groups were signiﬁcantly different at the pre-
operative visit (7.2 ± 2.6 vs. 9.4 ± 1.3, respectively; p ¼ 0.002) and
postoperative visit (3.8 ± 2.9 vs. 6.7 ± 3.2, respectively; p ¼ 0.02),
although the improvement in the score was not signiﬁcantly
different (p ¼ 0.65).
There was no loss to follow up. Twenty-three patients had a
follow up > 1 year. Of these, 13 of 23 (56%) patients only had one
injection and were observed because of cure or signiﬁcant
improvement that did not require additional therapy. By contrast,
seven of 23 (30%) patients had a repeat injection, two of 23 (9%)
patients had a sling placed, and one of 23 (4%) patients had an AUS.Table 3
Literature review on Macroplastique.
Study Design Follow-up
period (mo)
N Improvement
rate (%)
Ghoniem et al15 Randomized,
single-blind
12 mo 247 61.5
Ghoniem et al13 Case series 24 mo 67 84
Maher et al14 Randomized
controlled trial
12 mo 23 60
Plotti et al16 Case series 12 mo 24 42
Tamanini et al12 Case series 60 mo 15 33.3
Zullo et al17 Prospective
cohort study
12 mo 27 33
PDMS ¼ XX.
Please cite this article in press as: Rosenfeld EC, et al., Macroplastique outc
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We report our early experience with MPQ, which indicates an
overall success rate of nearly 70% and a slightly higher success rate
in the naïve subgroup. In a subset of womenwho underwent repeat
3DUS testing over time, no signiﬁcant loss of volume was noted.
Even though absolute cure or strict dryness after MPQ is only
achieved in a minority of patients, MPQ provided durable SUI
symptom improvement in most of our patient population. No
changes in Question 5 of UDI-6 related to voiding, maximum ﬂow,
or postvoid residual were noted, which implies no effect on voiding
function.
Several series on bulking agents have been reported in the
literature such as a recent large series of 514 women treated with a
variety of bulking agents within the past 13 years.8 However,
limited data is available on Macroplastique and the use of an
objective outcome measure such as the one employed in this study
with 3DUS. A study by Hegde et al,9 which used 3DUS to evaluate
MPQ outcomes at 15 minutes after the procedure, demonstrated
that a better clinical outcome was associated with MPQ location in
the proximal urethra and with a circumferential periurethral dis-
tribution. In the Hedge study (N ¼ 100) divided treatment-naïve
patients into groups based on their clinical outcomes: patients with
a good outcome (Group A; N ¼ 72) and patients who either wors-
ened or did not improve after injection (Group B;N¼ 28). Themean
follow up was 19.32 weeks in Group A and 17.77 weeks in Group B.
In our study, we did not perform ultrasound to determine im-
mediate results, but to evaluate the durability of the injection in
volume and conﬁguration around the urethra in different clinical
subgroups of women. All studies were performed approximately
6e8 weeks after the injection procedure as part of the ﬁrst follow-
up visit. We have previously reported on the use of 3DUS, and
focused on evaluating the mid- and long-term results of Collagen
injections for SUI.2,3 These studies together demonstrate that
circumferential distribution of an injectable agent is a more
important predictor of favorable outcome than the injected volume
and that 3DUS is a simple tool to serially and objectively evaluate
UBA distribution.
Variable improvement and cure rates for MPQ have been re-
ported in contemporary literature (Table 3)12e14. A recent meta-
analysis by Ghoniem and Miller10 described cure rates of 45%
(short-term outcome) and 36% (long-term outcome), whereas the
improvement rates were 75% (short-term outcome) and 65%
(longeterm outcome). Variability between reports is associated
with indications, success deﬁnition, and duration of follow up. OurCure/dry
rate (%)
Success determinant Adverse effects
36.9 Stamey grade 24% UTI,
9% dysuria,
9% urgency,
8% frequency,
7% retention
67 Stamey grade None reported
n/a Patient report 5% voiding dysfunction
42 Urodynamic assessment None reported
40 Urodynamic assessment 10.3% transient urinary
retention; 4.8% loss of PDMS
through injection site
44 Urodynamic assessment None reported
ome inwomenwith stress urinary incontinence secondary to intrinsic
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consistent with these literature ﬁndings.
The MPQ deserves special attention as a salvage treatment
posteanti-incontinence procedure because it has been under-
reported in the literature. Lee-Lewis and Anderson11 reported a
34.8% cure rate and a 77% improvement rate in women treated for
recurrent SUI after a prior mid-urethral sling (MUS). In a study by
Gumus et al,1 which compared women with and without a history
of an anti-incontinence operation, the women who had undergone
a prior procedure for SUI were more satisﬁed with their condition
post-MPQ in a long-term follow up. Different expectations between
the two groups may have affected their response rates. Our own
study suggests the same adaptation of women to their incontinence
condition after a prior failed anti-incontinence procedure with
improvement but not complete cure being well accepted.
Long-term favorable outcome has been reported by Tamanini
et al12 at 12months, 24months, and 60months,which indicated the
relative durability and stability of theMPQ. Ghoniem et al13 likewise
reported that 84% of patients maintained signiﬁcant Stamey grade
improvement at their 12e24month assessments.11 However,Maher
et al14 reported a continence rate of only 22% post-MPQ at the 60-
month follow up; however, these lower values for long-term ﬁnd-
ings were obtained from a nonvalidated questionnaire.
Our study has unique strengths. It was a prospective study on
womenwith different SUI backgrounds ranging from naïve to prior
sling procedure with or without an additional bulking agent. The
data was collected and analyzed by a neutral investigator not
involved in patient care. The 3DUS procedure was performed by the
same team of technicians and radiologists with longstanding
expertise of more than a decade in 3DUS interpretation after
collagen injection.
The limitations of this study include its short-term follow-up
period and its relatively limited study size. However, it is one of the
largest cohorts reported to date. In addition, because 3DUS was not
performed immediately at the time of the injection under anes-
thesia, it was not possible to determine if failures were because of
substance migration or extrusion, or operative/technical failure.
5. Conclusion
MPQ is apparently an effective treatment option in the short-
term in women with naïve or complicated ISD-related SUI. A
complete cure is only achieved in a minority of patients, although a
signiﬁcant improvement was observed by many women. Three-
dimensional vaginal ultrasound can be used to assess andPlease cite this article in press as: Rosenfeld EC, et al., Macroplastique outco
sphincteric deﬁciency, Urological Science (2015), http://dx.doi.org/10.101monitor MPQ injection results over time, and has demonstrated
stable volumes in a subset group.Conﬂicts of interest
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